Literature DB >> 1901333

Tumor necrosis factor (cachectin) in human visceral leishmaniasis.

M Barral-Netto1, R Badaró, A Barral, R P Almeida, S B Santos, F Badaró, D Pedral-Sampaio, E M Carvalho, E Falcoff, R Falcoff.   

Abstract

High tumor necrosis factor-alpha (TNF alpha) levels were present in the serum of 24 of 28 active visceral leishmaniasis (VL) patients (142.9 +/- 113.9 pg/ml, mean +/- SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNF alpha levels were also not elevated in 15 normal volunteers (11.3 +/- 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 +/- 10.8 pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNF alpha production by these cells, and this effect was further potentiated by treatment with recombinant interferon-gamma. After effective treatment of VL patients, serum TNF alpha levels dropped rapidly (129 +/- 112 vs. 9 +/- 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 +/- 69 vs. 155 +/- 71 pg/ml in 10 days). Thus, serum TNF alpha levels in VL patients are a good parameter to monitor in determining host response to therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901333     DOI: 10.1093/infdis/163.4.853

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Mannan-binding lectin enhances susceptibility to visceral leishmaniasis.

Authors:  I K Santos; C H Costa; H Krieger; M F Feitosa; D Zurakowski; B Fardin; R B Gomes; D L Weiner; D A Harn; R A Ezekowitz; J E Epstein
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis.

Authors:  Fabiano Oliveira; Andre Bafica; Andrea B Rosato; Cecilia B F Favali; Jackson M Costa; Virginia Cafe; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

5.  Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Authors:  Carmel B Stober; Selma M B Jeronimo; Nubia N Pontes; E Nancy Miller; Jenefer M Blackwell
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

6.  Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection.

Authors:  Theresa M Karplus; Selma M B Jeronimo; Haeok Chang; Bethany K Helms; Trudy L Burns; Jeffrey C Murray; Adele A Mitchell; Elizabeth W Pugh; Regina F S Braz; Fabiana L Bezerra; Mary E Wilson
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

9.  Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection.

Authors:  F J Medrano; C Rey; M Leal; C Cañavate; A Rubio; A Sánchez-Quijano; J Alvar; E Lissen
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

10.  Transforming growth factor-beta in human cutaneous leishmaniasis.

Authors:  A Barral; M Teixeira; P Reis; V Vinhas; J Costa; H Lessa; A L Bittencourt; S Reed; E M Carvalho; M Barral-Netto
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.